688273.SHG Nanjing Medlander Medical Technology Co. Ltd. A
- Market cap
- CNY 2.56B
- P/E
- 37.7x
- P/B
- 1.84x
- ROE
- 5.5%
- Dividend yield
- 2.68%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688273.SHG undervalued?
Graham number688273.SHG trades 75.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nanjing Medlander Medical Technology Co. Ltd. A fundamental analysis
No fundamental analysis for Nanjing Medlander Medical Technology Co. Ltd. A yet.
Nanjing Medlander Medical Technology Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nanjing Medlander Medical Technology Co. Ltd. A
Nanjing Medlander Medical Technology Co.,Ltd. engages in the research and development, manufacture, sale, and service of pelvic floor rehabilitation equipment and related products in China and internationally. It offers pelvic floor and obstetrics and gynecology rehabilitation, reproductive rehabilitation and anti-aging product, and sports rehabilitation products, as well as consumables and IT products, such as vaginal electrodes, rectal electrodes, and vaginal probes. The c…
Full company profileNanjing Medlander Medical Technology Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nanjing Medlander Medical Technology Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 337M | 342M | 377M | 341M | 425M | 432M | 386M |
| Gross Profit | 256M | 249M | 258M | 242M | 306M | 303M | 257M |
| Operating Income | 135M | 125M | 132M | 74.4M | 113M | 102M | 65.4M |
| EBITDA | - | - | 161M | 120M | 153M | 137M | 70.2M |
| Net Income | 122M | 118M | 122M | 89.8M | 102M | 103M | 73.5M |
| EPS | 1.63 | 1.58 | 1.22 | 0.89 | 1.02 | 1.03 | 0.73 |
| Balance Sheet | |||||||
| Total Assets | 336M | 489M | 1.51B | 1.53B | 1.55B | 1.63B | 1.61B |
| Total Liabilities | 88.7M | 116M | 142M | 159M | 200M | 260M | 255M |
| Shareholders' Equity | 240M | 363M | 1.35B | 1.35B | 1.31B | 1.35B | 1.34B |
| Cash & Short-term Investments | 150M | 273M | 1.18B | 992M | 462M | 816M | 367M |
| Cash Flow | |||||||
| Operating Cash Flow | 131M | 149M | 127M | 137M | 123M | 105M | - |
| Capital Expenditure | 25.9M | 14.6M | 54.3M | 75.1M | 130M | 118M | 64.8M |
| Free Cash Flow | 105M | 134M | 72.4M | 61.8M | -7.20M | -12.7M | -84.2M |
| Ratios | |||||||
| ROE | 50.7% | 32.6% | 9.0% | 6.7% | 7.7% | 7.6% | 5.5% |
| ROA | 36.3% | 24.2% | 8.0% | 5.9% | 6.6% | 6.3% | 4.6% |
| Net Profit Margin | 36.2% | 34.7% | 32.3% | 26.4% | 23.9% | 23.8% | 19.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Nanjing Medlander Medical Technology Co. Ltd. A dividends
- Dividend yield
- 2.68%
- Forward dividend
- 0.80 CNY
- Payout ratio
- 66.9%
- Ex-dividend date
- May 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 68.7M | 0.69 | 66.9% |
| 2024 | CNY 98.9M | 0.99 | 97.4% |
| 2023 | CNY 82.2M | 0.82 | 91.5% |
| 2022 | CNY 50.0M | 0.50 | 41.1% |
| 2021 | CNY 32.6K | 0.00 | 0.0% |
| 2020 | CNY 54.1M | 0.72 | 44.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Nanjing Medlander Medical Technology Co. Ltd. A
- Insiders 65.41%
- Institutions 2.40%
- Public & others 32.20%
- Shares outstanding 100M
- Free float 31.6M
Nanjing Medlander Medical Technology Co. Ltd. A company profile
- Company name
- Nanjing Medlander Medical Technology Co. Ltd. A
- Ticker
- 688273.SHG
- ISIN
- CNE100005PV8
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 550
- Fiscal year end
- December
- Address
- North Building A2, Nanjing, China, 210012
- Phone
- 86 400 826 9888
- Website
- medlander.com
About Nanjing Medlander Medical Technology Co. Ltd. A
Nanjing Medlander Medical Technology Co.,Ltd. engages in the research and development, manufacture, sale, and service of pelvic floor rehabilitation equipment and related products in China and internationally. It offers pelvic floor and obstetrics and gynecology rehabilitation, reproductive rehabilitation and anti-aging product, and sports rehabilitation products, as well as consumables and IT products, such as vaginal electrodes, rectal electrodes, and vaginal probes. The company also provides electronic colposcopes, biofeedback stimulation devices, high-frequency electrocautery devices, ultrasonic uterine involution devices, and electro-ultrasound therapy devices; and finger joint rehabilitation assessment systems, portable hand function rehabilitation assessment systems, hand function magnetic stimulation systems, transcranial magnetic stimulation systems, biofeedback devices, and portable biofeedback devices. In addition, it provides pelvic floor muscle rehabilitation devices and power recliner. It serves clients in gynecology, obstetrics, rehabilitation, proctology, postpartum recovery centers, and urology areas. The company was founded in 2013 and is headquartered in Nanjing, China.
Nanjing Medlander Medical Technology Co. Ltd. A management
8- Mr. Ruijia YangChairman of the Board & GM · born 1978
- Ms. Ning XuCFO & Accounting Supervisor · born 1986
- Mr. Bin ChenDirector & Deputy GM · born 1976
- Mr. Zhihuai ShiDeputy GM & Director · born 1975
- Ms. Jiangning ChenDeputy GM & Board Secretary · born 1977
- Mr. Wang WangDeputy General Manager · born 1982
- Mr. Honglin TuDeputy GM & Director · born 1980
- Ms. Lu FanCore Technical personnel · born 1986